2 Healthcare Stocks Wall Street Analysts Say Could Rally 60% or More

Viking Therapeutics completed enrollment in a pivotal phase 3 trial for VK2735 with a readout expected next year and an oral phase 3 slated to begin in Q3; analysts have set price targets of $107 (Canaccord) and $125 (BTIG), underpinning bullish, high-upside expectations. HCA Healthcare reported same-facility admissions +2.4% YoY in Q4 2025 and revenue up ~7% to $19.5B, with management guiding for up to ~6% top-line growth this year and deploying AI (Timpani) to ease nurse-staffing bottlenecks. Overall, Viking is a high-risk/high-reward biotech exposure tied to regulatory outcomes, while HCA is a more stable, long-term healthcare-system play likely to move individual stocks rather than the broader market.

Analysis

VKTX sits in a classic high-conviction/high-binary bucket where market value will be dominated by one or two readouts and the implied probability of commercial differentiation. If the molecule demonstrates even modest superiority on speed-of-weight-loss or oral bioavailability versus incumbents, pricing dynamics will shift from per-patient chronic pricing toward a tiered-pricing market with premium launches followed by rapid rebate-driven discounting; that creates a short window for outsized M&A arbitrage but a multi-year margin compression story thereafter.

HCA’s edge is operational — marginal margin expansion from better staffing/throughput has asymmetric value because hospitals convert incremental admissions to free cash flow quickly; each percentage point of paid capacity lifts free cash flow materially. Second-order winners include capital-light outpatient conversion and software partners that embed into scheduling/staffing, while losers include high-cost contract nursing and regional smaller systems unable to invest in AI orchestration.

Key risks and timing: VKTX is a near-term binary (months to ~12 months) where volatility and tail risk are very high; downside is nearly total capital loss on a failed outcome but upside includes acquisition or re-rating of multiples. HCA is a multi-quarter story tied to cadence of admissions, length-of-stay improvements and wage inflation normalization; macro-induced elective-volume shocks or regulatory reimbursement changes are the main reversal vectors.

Key Decisions for Investors

• VKTX: Tactical asymmetric — buy a 9–12 month call spread sized to 1.5–2.5% of NAV (buy 30-delta call / sell 70-delta call) to cap premium outlay while retaining >3x upside if the trial readout re-prices the equity. Complement with 0.5% NAV in short-dated puts as income if implied vol is elevated; max loss = premium paid, target upside >300% on spread move.
• VKTX / NVO pair: long VKTX (1.5% NAV) / short NVO (0.5% NAV) to isolate idiosyncratic launch upside while limiting broad-class risk. Rationale: captures asymmetric takeover/launch upside of VKTX while offsetting a portion of system-wide pricing compression; rebalance post-readout. Risk: incumbent defensive pricing or biology undermines VKTX — stop 30% on the long leg.
• HCA: Buy-and-accumulate for 12–36 months — initiate a 2% NAV position in equity and hedge transient downside with a 6–9 month 5–10% OTM protective put (cost ~0.5–1% NAV) to protect against macro elective-volume shocks. Reward: 12–36 month IRR target 15–25% driven by margin capture and multiple re-rating if AI staffing KPIs show measurable improvement.
• Event hedges: If implied vol on VKTX spikes into key windows, consider selling 2–4 week strangles around non-critical events and redeploy into the 9–12 month call spread to monetize short-term vol and keep asymmetry intact. Manage total biotech exposure to <5% NAV to limit portfolio-level binary risk.